CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Metastatic Biliary Tract Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

MD Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Ian Hu, MD) · GIClinicalTrials@mdanderson.org · 713-792-2828
Contact: Principal Investigator (Ian Hu, MD)

Study leads

Ian Hu, MD
Principal Investigator
M.D. Anderson Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Metastatic Biliary Tract Cancer · Metastatic Biliary Tract Carcinoma

Abroad (travel likely)RecruitingPHASE1

St Louis, United States

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Endometrial Cancer · Gastric Cancer · Metastatic Castration-resistant Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

Los Angeles, United States · San Diego, United States

Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer

Locally Advanced Biliary Tract Cancers · Metastatic Biliary Tract Cancers

Abroad (travel likely)Recruiting

Seongnam-si, South Korea

AB122 Platform Study

Advanced or Metastatic Solid Tumor · Pancreatic Ductal Adenocarcinoma · Colorectal Cancer

Abroad (travel likely)RecruitingPHASE1

Aichi, Japan · Chiba, Japan